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Liver X receptor (LXR)Adaptations in the oxidative capacity of skeletal muscle cells can occur under several physiological or
pathological conditions. We investigated the effect of increasing extracellular glucose concentration on the
expression of markers of energy metabolism in primary skeletal muscle cells and the C2C12 muscle cell line.
Growth of myotubes in 25 mM glucose (high glucose, HG) compared with 5.55 mM led to increases in the
expression and activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a marker of glycolytic
energy metabolism, while oxidative markers peroxisome proliferator-activated receptor γ coactivator 1α and
citrate synthase decreased. HG induced metabolic adaptations as are seen during a slow-to-fast ﬁber
transformation. Furthermore, HG increased fast myosin heavy chain (MHC) IId/x but did not change slow
MHCI/β expression. Protein phosphatase 2A (PP2A) was shown to mediate the effects of HG on GAPDH and
MHCIId/x. Carbohydrate response element-binding protein (ChREBP), a glucose-dependent transcription
factor downstream of PP2A, partially mediated the effects of glucose on metabolic markers. The glucose-
induced increase in PP2A activity was associated with an increase in p38 mitogen-activated protein kinase
activity, which presumably mediates the increase in MHCIId/x promoter activity. Liver X receptor, another
possible mediator of glucose effects, induced only an incomplete metabolic shift, mainly increasing the
expression of the glycolytic marker. Taken together, HG induces a partial slow-to-fast transformation
comprising metabolic enzymes together with an increased expression of MHCIId/x. This work demonstrates a
functional role for ChREBP in determining the metabolic type of muscle ﬁbers and highlights the importance
of glucose as a signaling molecule in muscle.me A acyltransferase 2; ACC,
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Skeletal muscle is composed of ﬁbers with different contractile and
metabolic properties [1]. Depending on these properties, muscleﬁbers are classiﬁed into different types: fast contracting with high
glycolytic metabolic capacity (FG), fast contracting with high
oxidative as well as high glycolytic metabolic capacity (FOG), and
slow contracting with high oxidative metabolic capacity (SO). Adult
skeletal muscle ﬁbers show plasticity, which means they have the
ability to change their ﬁber type to adapt to different physiological
demands, a process called ﬁber type transformation.
Changes in the metabolic proﬁle can occur during physiological as
well as pathological processes. Adaptations of metabolic properties
towards higher oxidative capacity can be induced by exercise in vivo
[2]. Endurance exercise-induced metabolic ﬁber type transformation
is characterized by increases in muscle oxidative capacity and
mitochondrial gene expression [3] in conjunction with a decrease in
anaerobic-glycolytic capacity. This transformation is often accompa-
nied by changes in the isoform pattern of contractile proteins and
many other functionally important muscle proteins. We consider here
mainly the changes inmetabolic enzymes associatedwith this process
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transformation process “metabolic ‘fast-to-slow’ transformation.”
AMP-activated protein kinase (AMPK) and the protein phosphatase
calcineurin are thought to play important roles in the regulation of
skeletal muscle energymetabolism in response to changes in the level
of energy status and neural input [4]. An important downstream
target of AMPK and calcineurin is the peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α), a transcriptional
coactivator and master regulator of mitochondrial oxidative metab-
olism [5,6]. Interestingly, several studies have demonstrated that
patients with type 2 diabetes show an increased ratio of glycolytic to
oxidative enzymes associated with a decrease in oxidative capacity
[7–9]. In accordance, such patients show a decrease in slow oxidative
type I ﬁbers.
Early evidence that intracellular Ca2+ can mediate the effects of
chronic repetitive muscle contractions on enzymes of energy
metabolism has been presented by experiments with cultured rat
myotubes, in which a transformation from glycolytic to oxidative
energy metabolism was evoked by Ca2+-ionophore [10]. Indeed, we
were able to induce a complete fast-to-slow transformation compris-
ing myosin heavy chain (MHC) isoforms and enzymes of energy
metabolism in adult primary rabbit skeletal myotubes by increasing
the intracellular Ca2+-concentration ([Ca2+]i) with Ca2+-ionophore
A23187 [11–13]. In addition, a Ca2+-ionophore-induced metabolic
transformation was also demonstrated on the promoter level in
C2C12 myotubes [14]. Moreover, Ca2+-ionophore treatment has been
shown to lead to protein kinase C (PKC)-dependent increases in the
expression of cytochrome c and cytochrome oxidase (COX) subunit
mRNAs as well as in AMPK phosphorylation in L6E9myotubes [15,16].
Furthermore, it has been demonstrated that calcineurin-dependent
activation of NFAT and a fast-to-slow transformation of myotubes
occur during the series of intracellular Ca2+-transients elicited by
repetitive contractile activity of primary rabbit myotubes [17]. These
data clearly indicate the importance of changes in [Ca2+]i for
metabolic transformations.
Recently we showed that primary skeletal muscle cells in culture
adapt to a reduction in glucose supply with an AMPK-independent
metabolic “fast-to-slow” transformation, as demonstrated by
decreases in glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and increases in mitochondrial acetyl-CoA thiolase (MAT), PGC-1α,
and citrate synthase (CS) [14]. Indeed, in several systems glucose has
emerged as an important regulator of gene expression [18]. Two
major candidate transcription factors for the transduction of an effect
of intracellular glucose on the expression of metabolic enzymes,
carbohydrate response element-binding protein (ChREBP) and liver X
receptor (LXR), have been discussed [18,19] and are investigated in
the present work. Both have so far mainly been studied in
hepatocytes, pancreatic β cells and adipocytes. Dietary uptake of
carbohydrates increases the expression of more than a dozen
glycolytic and lipogenic enzymes in liver, resulting in fatty acid
synthesis. Although insulin has long been known to be critical in
regulating the expression of some of these genes, it has been shown
that glucose itself also plays an important role in transcriptional
regulation. This impact of glucose was shown to be transduced via the
transcription factor ChREBP, whereas the sterol regulatory element
binding protein 1c (SREBP-1c) has emerged as a key mediator of the
insulin effects [20–22]. ChREBP is a basic helix–loop–helix leucine
zipper transcription factor that increases expression of liver glycolytic
and lipogenic genes in times of glucose abundance [22]. ChREBP is
most highly expressed in liver, brown and white adipose tissue, small
intestine, kidney and skeletal muscle [23]. While the physiological
function of ChREBP has been studied extensively in liver, its role in
skeletal muscle remains unclear. The activity of ChREBP is mainly
regulated at the post-transcriptional level by a phosphorylation/
dephosphorylation mechanism that controls the nuclear localisation
and the DNA-binding activity of ChREBP [24]. This glucose-dependentactivation of ChREBP was originally attributed in hepatocytes to
dephosphorylation of cAMP-dependent phosphorylation sites. The
protein phosphatase 2A (PP2A) has been shown to be activated by
xylulose 5-phosphate (X-5-P), a product of glucose metabolism, and
to be responsible for dephosphorylation of ChREBP [25]. PP2A is a
ubiquitously expressed major cellular serine/threonine phosphatase
[26]. An alternative model was proposed in the pancreatic β-cell line
832/13, postulating a release of an N-terminal intramolecular
inhibitory domain under high glucose conditions [27–29]. Target
genes of ChREBP, like liver pyruvate kinase (L-PK), acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS), feature so-called
carbohydrate response elements (ChoREs) in their promoter regions
that can directly bind ChREBP together with its partner Max-like
factor X [30–32]. Loss of ChREBP in ChREBP−/− mice results in
impaired glucose ﬂux through the glycolytic pathway in liver related
to diminished expression of L-PK. These mice display glucose and
fructose intolerance [23]. Moreover, ChREBP has been linked to insulin
resistance in leptin-deﬁcient (ob/ob) mice [33].
Other important transcription factors in glucose-dependent gene
regulation are LXRα and β. LXRs are key regulators of cholesterol and
lipidmetabolism and are also involved in glucose homeostasis [34,35].
They belong to the nuclear hormone receptor superfamily and form
heterodimers with retinoid X receptors. LXRs are capable of increasing
the transcription of ChREBP [19,36] and of SREBP-1c [37,38] via
functional LXR-binding sites in the respective promoter regions. It has
been demonstrated that in addition to activation by their “classical”
ligands, the oxysterols, LXRα and β can be activated by D-glucose and
D-glucose-6-phosphate (G-6-P) in vitro [19]. In humans, LXRβ is
ubiquitously expressed [39], whereas LXRα is restricted to tissues
with important roles in lipid metabolism like adipose tissue, liver,
skeletal muscle, kidney, and small intestine [40–42]. So far, several
studies have indicated a role of LXR in the regulation of cholesterol
homeostasis, lipid and glucose metabolism in skeletal muscle in vivo
and in vitro [43–48].
In the present study, we investigate the molecular mechanisms of
the effects of glucose on the expression of markers of glycolytic and
oxidative energy metabolism. We show that an increase in glucose
concentration induces a metabolic “slow-to-fast” ﬁber type transfor-
mation in cultured myotubes, and we demonstrate important
promotional roles of ChREBP and PP2A in this glucose-dependent
metabolic adaptation. Interestingly, high glucose concentration also
vincreases MHCIId/x gene expression, which is part of the complete
slow-to-fast transformation program as it has been observed in slow
rabbit muscles subjected to phasic high frequency electrostimulation
in vivo, but high glucose does not reduce MHCI/β gene expression,
which would also be expected in the course of slow-to-fast
transformation. The effect on the MHCIId/x promoter appears to be
mediated via PP2A and p38 mitogen-activated protein kinase (p38
MAPK). Thus, glucose induces a partial slow-to-fast transformation.
2. Materials and methods
2.1. Animals
New Zealand white rabbits were purchased via the Animal Facility
of Hannover Medical School and were euthanized in accordance to § 4
Tierschutzgesetz.
2.2. Primary cell culture
Skeletal muscle cells from hind limbs of newborn New Zealand
white rabbits were isolated and separated from ﬁbroblasts as
described previously [11]. Myoblasts were diluted to a ﬁnal
concentration of 6.5 x 105 cells/ml in complete Dulbecco's modiﬁed
Eagle's medium (DMEM; Invitrogen, Karlsruhe, Germany) containing
5.55 mM glucose, supplemented with 10% neonatal calf serum (NCS;
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a 75 cm2 cell culture ﬂask together with 0.04 g microcarriers (Culti-
Spher-GL; Percell Biolytica, Astorp, Sweden). Cellswere grownat 37 °C
with 8% CO2 and 90% humidity. On day 2 the medium was changed to
30 ml of Skeletal Muscle Growth Medium with 5% foetal calf serum
(FCS) and supplements (PromoCell, Heidelberg, Germany). On day 4,
half of the medium was replaced. On day 7, the medium was changed
to DMEMwith 10% rabbit serum (PAN-Biotech, Aidenbach, Germany).
On day 9, the medium was changed to DMEMwith 5% NCS. From this
day onwards, half of the medium was replaced every second or third
day. After 14 days in culture, myotubes had differentiated into adult,
fast glycolyticmuscle cells [11,12]. Fromday 14myotubeswere grown
in 0 mM, 5.55 mM (low glucose, LG), or 25 mM (high glucose, HG) for
4 or 7 additional days. Medium without glucose was supplemented
with 1 mM lactate. In some experiments, cells were treated with
0.2 μM Ca2+-ionophore A23187 (Sigma, Taufkirchen, Germany), and/
or 5 μM of the LXR agonists T0901317 or GW3965 (both from Sigma),
for 4 or 7 days as indicated in the respective ﬁgure legends.
2.3. RNA isolation and reverse transcription (RT)-PCR
For isolation of total RNA from primary rabbit myotubes, cells on
microcarriers were washed with phosphate buffered saline (PBS),
covered with RNA-Later (Ambion, Darmstadt, Germany) and stored at
−20 °C. RNA isolation was carried out with the RNeasy Kit (Qiagen,
Hilden, Germany) including digestion of genomic DNA. cDNA was
synthesized from 1.5 μg of total RNA using Omniscript Reverse
Transcriptase (Qiagen), according to the manufacturer's instructions.
Semi-quantitativemultiplex PCRwas performed using the HotStarTaq
DNA Polymerase Kit (Qiagen), primers for the cDNA of interest and
the QuantumRNA 18S Internal Standards Kit (Ambion) for normal-
isation. The PCR program consisted of cycles of 95 °C for 1 min
followed by 60 °C for 1 min and 72 °C for 1 min, after an initial
activation of the HotStarTaq at 95 °C for 15 min. PCR with primers
speciﬁc for 18s rRNA was performed for normalisation of transcript
levels. For every new set of samples, including controls, the
exponential range of PCR ampliﬁcation and the appropriate ratio of
18S primers to 18S competimers (Ambion) was determined in
preliminary experiments. The PCR primers used were as follows:
GAPDH (GenBank accession no. L23961)
forward primer: 5′-CCT GCG ACT TCA ACA GTG C-3′
reverse primer: 5′-GCC TCT CGT CCT CCT CTG-3′
HK-2 (GenBank accession no. NM_012735)
forward primer: 5′-TGC TGG TGC GTG TGC GTA ATG G-3′
reverse primer: 5′-AGG CTG TTC TGC TGG CAA GGG AAG G-3′
PGC-1α (GenBank accession no. AB025784)
forward primer: 5′-CAA ACT TGC TAG CGG TCC TC-3′
reverse primer: 5′-GTG TGG TTT GCA TGG TTC TG-3′.
PCR products were separated in an 8% total acrylamide-bisacry-
lamide/5% bisacrylamide polyacrylamide gelelectrophosis (PAGE),
using Low DNA Mass Ladder (Invitrogen) as a marker, followed by
highly sensitive silver staining [49]. Densitometric quantiﬁcation of
target cDNA and 18S cDNA bands was performed with an Image
Master System (GE Healthcare, München, Germany).
For semiquantitative RT-PCR analysis of MHC isoform mRNA
expression, total RNA from C2C12 myotubes was isolated using
NucleoSpin RNAII kit (Macherey & Nagel, Düren, Germany). mRNA
was reverse transcribed and cDNA ampliﬁed with Phusion® RT-PCR
Kit (New England Biolabs, Frankfurt, Germany) according to the
manufacturer's instruction. PCR was performed in a reaction of 50 μl
with maximum cycle number of 35. PCR products were analyzed by
2% agarose gel electrophoresis and visualized with ethidium bromide
staining. Primer pairs used were: mouseMyHCI/β forward (F): 5′-GCT
GAG GCC CAG AAA CAA G-3′, and reverse (R): 5′-TTC CAC GAT GGCGAT GTT C-3′; mouseMyHCIId/x F: 5′-ACG CTGGAT GCT GAG ATT AG-
3′, and R: 5′-GAG TGG TTC AGC TGG ATT TC-3′; mouse 18s rRNA F: 5′-
GGA CCA GAG CGA AAG CAT TT-3′, and R: 5′-TGC CAG AGT CTC GTT
CGT TAT-3′.
2.4. Analysis of GAPDH and CS enzymatic activities
The GAPDH enzyme activity assay was performed in triethanola-
mine buffered solution containing 82.5 mM triethanolamine (pH 7.6),
6 mM glycerate-3-phosphate, 1.7 mM MgSO4, 1.1 mM ATP, 0.9 mM
EDTA, 0.2 mMNADH, 14.8 U/ml phosphoglycerate kinase and sample,
which had been stabilized by 5 mMDTT. ΔE(340 nm)/t wasmeasured
at 30 °C. The CS enzyme activity was analysed photometrically as
described [50]. Brieﬂy, the reaction mixture contained 100 μM Tris-
EDTA (pH 8.0), 5 μM NAD+, 6 μM malate, 60 μg/ml malate dehydro-
genase, sample and 0.22 μM acetyl-coenzyme A. ΔE(340 nm)/t was
measured at 30 °C. Enzyme activities were normalised to total protein
concentration of cell homogenates.
2.5. Analysis of glycogen content
To analyse glycogen content, muscle cell homogenates were ﬁrst
treated with 0.4 M KOH at 100 °C for the destruction of intracellular
free glucose and denaturation of cellular protein. This was followed by
enzymatic hydrolysis of glycogen and analysis of free glucose from
glycogen as described [51]. For determination of the free glucose
concentration, absorbance of an assay containing 200 mM Tris, 3 mM
ATP, 2 mM MgCl2, 0.33 mM NADP+, 0.9 U/ml glucose-6-phosphate
dehydrogenase, 0.7 U/ml hexokinase and sample was read at 340 nm.
Free glucose concentrations were normalised to total protein
concentration of cell homogenates.
2.6. Plasmid construction
A −2183 bp mouse GAPDH (EC 1.2.1.12) promoter fragment was
generated from Mus musculus genomic DNA by high-ﬁdelity long
range PCR (GeneAmp XL PCR Kit, Perkin Elmer Applied Biosystems,
Waltham, MA, USA) using speciﬁc primers (forward primer: 5'-ACG
TAGATC TAATGACTCAGCCTGGCTAATGG-3', reverse primer: 5'-ACT
GAA GCT TTT GCA CAC TTC GCA CCA GCA TC-3'). The promoter
fragment was cloned into the luciferase reporter gene vector pGL3-
Basic (Promega, Mannheim, Germany). A −2281 bp promoter
fragment of mouse mitochondrial acetyl-Coenzyme A acyltransferase
2 (ACAA-2; EC 2.3.1.16) was also generated by PCR (forward primer:
5'-ACGTAGATC TTAGGTGTACCTACC TAAATAGC-3', reverse primer:
5'-ACTGAAGCT TCT TAATGCAAACAGTGTCCACC-3') and cloned into
pGL3-Basic. To generate an mGAPDH promoter mutated in the
putative carbohydrate response element (ChoRE) (−1545/−1529)
the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, Amster-
dam, The Netherlands) was used according to the manufacturer's
instructions. Nucleotides CAC (−1545/−1543 bp) in the 5' half of the
5' E-Box-like element of the putative ChoREweremutated to ATA. The
−2.4 kb MHCI/ß and the −2.8 kb MHCIId/x promoter luciferase
constructs were described previously [52]. The mChREBP expression
plasmid pCMVS4-ChREBP was a gift from Dr. H. C. Towle [32].
2.7. Cell culture and transfection
Mouse C2C12 myoblasts (American Type Culture Collection,
Wesel, Germany) were cultured on Petri dishes in growth medium
(GM), consisting of complete DMEM (Invitrogen) containing 5.55 mM
(low glucose, LG) or 25 mM glucose (high glucose, HG) supplemented
with 10% FCS (Sigma). Cells were transfected at 50–60% conﬂuence
with 1.5 μg of reporter plasmid, 1.5 μg of pSV-β-Galactosidase
(Promega) and 2.5 μl/μg DNA of Lipofectamine 2000 Transfection
Reagent (Invitrogen). In some experiments, 0.75 μg of pCMVS4-
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transfection. The transfection mediumwas removed after 5 hours and
replaced by GM. After a further period of 24 hours, GM was replaced
by differentiation medium (DM; DMEM containing 5.55 mM or
25 mMglucose and 5% horse serum (HS; Biochrom, Berlin, Germany))
for 2 days and cells were subsequently harvested for luciferase assays.
In some experiments, cells were treated with 0.1 μM of Ca2+-
ionophore A23187 (Sigma), or 10 μM of LXR agonist T0901317
(Axxora, Grünberg, Germany), or 10 nM of PP2A inhibitor okadaic
acid (Sigma), during the ﬁnal 2 days of culture.
2.8. Reporter gene assays
Cells were lysed in 400 μl 1× Reporter Lysis Buffer (Promega).
Twenty μl of lysate were used in a luciferase assay using a Lumat
Luminometer (Berthold Technologies, Bad Wildbach, Germany)
measuring relative light units (RLU). The luciferase assay reagent
was composed of 200 mM tricine, 10.7 mM (MgCO3)4Mg(OH)2,
26.7 mM MgSO4, 333 mM dithiothritol, 5.3 mM ATP, 2.74 mM
coenzyme A and 470 μM D-luciferin (Applichem, Darmstadt,
Germany). Cells were co-transfected with pSV-β-Galactosidase
(Promega) as an internal reference. The β-galactosidase activity
(β-Gal) was estimated by a standard colorimetric assay [53].
Alternatively, the Luminescent β-galactosidase Reporter System 3
(Clontech, Takara Bio Europe, St. Germain-en-laye, France) was used
according to the manufacturer's instructions.
2.9. RNA interference assays
C2C12 myoblasts transfected with mACAA-2 or mGAPDH promot-
er reporter plasmid were additionally transfected after 1 day in GM
with 0.825 μg of a pool of doublestranded 20–25 nt siRNA that
speciﬁcally targets mouse ChREBP or LXRα, or with non-speciﬁc
double stranded control siRNA (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), and siRNA Transfection Reagent (8 μl/μg of respective
siRNA; Santa Cruz Biotechnology, Inc.) according to the manufac-
turer's instructions. Cells were grown for another 2 days in DM under
LG or HG conditions, in some experiments with 10 μM of LXR agonist
T0901317.
2.10. Intracellular fractionation and Western blot analysis
C2C12 cells were grown for 2 days in DM containing 5.55 mM or
25 mM glucose supplemented with 5% HS in the presence or absence
of okadaic acid (10 nM). In addition, C2C12 cells transfected with the
ChREBP expression vector or the empty vector were grown for 24
hours in GM and then for 2 additional days in DM containing 25 mM
glucose. Myotubes were washed with PBS, lysed and denatured with
SDS-PAGE sample buffer at 95 °C for 3minutes, followed by cooling on
ice. Equal amounts of total protein per lane were separated
electrophoretically in 10% SDS-PAGE and then transferred to a
nitrocellulose membrane. After blocking in PBS containing 1%
Tween and 5% low fat dry milk, blots were probed with anti-p38
antibody (Cell Signaling, New England Biolabs GmbH, Frankfurt,
Germany), anti-phospho-p38 (Thr-180,Tyr-182) antibody (Cell Sig-
naling), or anti-α-tubulin antibody (Santa Cruz Biotechnology, Inc.),
followed by incubation with anti-rabbit or anti-mouse horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnol-
ogy, Inc.). Signals were visualized by enhanced chemiluminescence
detection (Santa Cruz Biotechnology, Inc.).
In other experiments, C2C12 cells grown for 2 days in DM
containing 5.55 mM or 25 mM glucose supplemented with 5% HS
were suspended in cell fractionation buffer containing 5 mM Tris–HCl
(pH 7.4), 5 mM KCl, 1.5 mMMgCl2, 0.1 mM EGTA, 1 mM DTT, 0.2 mM
PMSF, 2 mM benzamidine and 5% (w/v) Trasylol for 5 min. For cell
fractionation, 0.1% NP40 was added into suspension. Cell extractswere centrifuged at 850 g. Pellet fraction and supernatant fraction
were lysed in Laemmli sample buffer. Western blot analysis was
performed using anti-ChREBP (Novus Biologicals, Littleton, CO, USA)
or anti-p53 (Santa Cruz Biotechnology, Inc.) antibodies. Bound
antibodies were detected with either anti-rabbit IgG or anti-mouse
IgG conjugated to horseradish peroxidase.
2.11. Chromatinimmunoprecipitation (ChIP) assay
C2C12 muscle cells were grown for 2 days in DM containing
5.55 mM or 25 mM glucose. ChIP assays were conducted using the
ChIP-IT Enzymatic Kit (Active Motif, Rixensart, Belgium) according to
the manufacturer's instructions. Brieﬂy, DNA and associated proteins
were crosslinked with 1% formaldehyde for 10 min at 37 °C. After
stopping the reaction by addition of 125 mMglycine, cellswerewashed
in PBS. Cells scraped from culture plates were re-suspended in Lysis
Buffer supplemented with Protease Inhibitor Cocktail and homoge-
nised. DNA was then enzymatically sheared for 10 min. After pre-
clearingwith Protein G beads, lysates were incubatedwith 2 μg of anti-
ChREBP antibody (Novus Biologicals) or negative control anti-IgG
antibody overnight at 4 °C. An aliquot of pre-cleared chromatin not
incubated with antibody served as input control. Antibody-bound
protein-DNA complexes were incubated with Protein G beads for
1.5 hours at 4 °C. The captured immunocomplexes, containing bound
DNA fragments,were eluted and treatedwithproteinaseK. The puriﬁed
DNA fragmentswere used in a PCRwith primers speciﬁcally amplifying
the native−1650/−1449 bpmouse GAPDH promoter region (forward
primer: 5'-GAC TCT GAA TCT GCC ATG CCT CTC-3', reverse primer: 5'-
CCA AAT CTA GTC TTG CCT TGC-3'). PCR products were separated on a
2% agarose gel and stained with ethidium bromide.
2.12. Analysis of metabolite concentrations
To measure intracellular glucose and G-6-P concentrations,
metabolites were extracted with 0.5 mM HClO4, 1 mM EDTA and
additional sonication at 0 °C. Extracts were centrifuged for 10 min at
0 °C with 15800 g, the supernatants were buffered with 1 M
imidazole, titrated to pH 6.8 by addition of 2.1 M KHCO3 and
centrifuged twice to remove KClO4. For determination of intracellular
glucose content the increase in ﬂuorescence of an assay containing
sample, 150 mM triethanolamine (pH 7.6), 25 mM MgCl2, 9 mM ATP,
3 mMNADP+, 6.3 U/ml G-6-P dehydrogenase (G-6-P-DH) and 22.5 U/
ml hexokinase to start the glucose-dependent NADPH formation was
measured ﬂuorimetrically with excitation and emission wavelengths
of 354 and 460 nm. The intracellular G-6-P content was measured by
reading the increase in ﬂuorescence of an assay containing sample,
150 mM triethanolamine (pH 7.6), 25 mM MgCl2, 3 mM NADP+ and
6.3 U/ml G-6-P-DH to start the G-6-P-dependent NADPH formation
with excitation and emission wavelengths of 354 and 460 nm.
Metabolite contents were normalised to total protein contents of
the samples as measured by a modiﬁed Bradford assay [54]. To obtain
cytosolic metabolite concentrations, the correlation between protein
content and cellular volume was determined and used to deduce
intracellular metabolite concentrations in mmol/l. The cellular
volume was calculated via cell count and average cell diameter,
which was determined on detached, spherical cells using a micro-
scope ﬁtted with a micrometre scale.
2.13. Statistical analysis
Results are expressed as means±SD of three or more independent
experiments. The statistical signiﬁcance of differences of these means
was estimated by one-way ANOVA followed by the Newman–Keuls
multiple comparison test, performed using GraphPad Prism software
version 3.00.
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To assess the impact of different treatments on energy metabo-
lism, we selected two sets of metabolic markers. As a marker of
anaerobic-glycolytic energy metabolism, we measured GAPDH en-
zyme activity, mRNA level, and promoter activity. As markers of
aerobic-oxidative energy metabolism we measured PGC-1α mRNA
level, CS enzyme activity and mitochondrial acetyl-Coenzyme A
acyltransferase 2 (ACAA-2) promoter activity. PGC-1α was measured
as a marker of mitochondrial biogenesis and oxidative muscle ﬁber
type characteristics, CS as a marker of the tricarboxylic acid cycle, and
ACAA-2 as a marker of mitochondrial fatty acid β-oxidation. In
addition we measured glycogen content and hexokinase 2 (HK-2)
mRNA level. Glycogen content is higher in fast-glycolytic than in slow-
oxidative muscle ﬁbers [55]. HK-2 is the ﬁrst enzyme of glycolysis, but
is highly expressed in slow-oxidative skeletal muscle [50]. This is
probably because fast-glycolytic muscle has large glycogen stores [56]
and is therefore able to produce sufﬁcient G-6-P from glycogen
without the action of hexokinase within its relatively short bouts of
activity. To describe shifts in the pattern of metabolic enzymes, we
will use the following the termsmetabolic “slow-to-fast” or metabolic
“fast-to-slow” transformation, indicating that the muscle cells
undergo changes in these enzymes either towards the pattern
prevailing in fast or in slow muscle ﬁbers. The terms do not imply
any changes in contractile protein isoforms.
3.1. High glucose conditions induce a metabolic
“slow-to-fast” transformation
To investigate the effects of high glucose concentrations, we used a
previously established primary rabbit skeletal muscle cell culture
[11,12]. Myotubes reach an adult state after 14 days in culture and are


































































































Fig. 1. High glucose conditions induce a metabolic “slow-to-fast” transformation in primary s
7 additional days in medium containing 0 mM, or 5.55 mM, or 25 mM glucose, with or with
energy metabolism (A) glycogen content, (B) GAPDH mRNA level, and (C) GAPDH enzyme a
mRNA level, (E) PGC-1αmRNA level and (F) CS enzyme activity were measured. The data re
medium containing 5.55 mM glucose (controls) were set to 100%. *=signiﬁcantly differe
pb0.05. ⊥=signiﬁcantly different from respective myotubes in medium containing 0 mM,enzymes of energy metabolism. Elevation of extracellular glucose
concentration ([glc]e) from 5.55 mM (low glucose, LG) to 25 mM
(high glucose, HG) for 7 days signiﬁcantly increases glycogen content,
GAPDHmRNA level and enzyme activity (Fig. 1A–C). Furthermore this
treatment signiﬁcantly decreases HK-2 mRNA level, PGC-1α mRNA
level, and CS enzyme activity (Fig. 1D–F). By contrast, a reduction of
glycolytic and an increase of oxidative markers were found when
myotubes grown in 0 mM glucose were compared with the LG
condition. In addition, we investigated the effect of HG conditions on
GAPDH and ACAA-2 promoter activities in transient transfection
assays in C2C12 myotubes, as efﬁcient transfections could not be
achieved in the primary carrier-grown culture. C2C12 myotubes also
predominantly express a fast ﬁber type in terms of MHC expres-
sion [52]. HG supply increased the activity of a −2.2 kb GAPDH and
decreased the activity of a −2.3 kb ACAA-2 promoter luciferase
reporter gene construct (Fig. 2A and B). These data further support the
ﬁnding of Fig. 1 that HG increases expression of glycolytic while
decreasing that of oxidative markers. Since HG treatment affects all of
the measured metabolic markers in both culture systems in the same
direction as seen during a slow-to-fast ﬁber type transformation, we
conclude that HG supply induces a metabolic 'slow-to-fast'
transformation.
Addition of 0.2 μM Ca2+-ionophore A23187 decreases glycogen
content, GAPDH mRNA level and enzyme activity (Fig. 1A–C) but
increases PGC-1α mRNA level and CS enzyme activity (Fig. 1E and F)
under LG and HG conditions, as well as in 0 mM glucose. Similarly,
Ca2+-ionophore treatment (0.1 μM) decreases GAPDH promoter
activity and increases ACAA-2 promoter activity under LG and HG
conditions (Fig. 2A and B). These data indicate that Ca2+-ionophore
can induce a metabolic 'fast-to-slow' transformation independent of
[glc]e. Furthermore, the effects of Ca2+-ionophore throughout are
contrary to the effects of HG. In turn, the ability of glucose to induce
changes in metabolic enzymes toward higher glycolytic capacity*
0 5.55 25
mM Glucose

































































keletal muscle cells. Fourteen day old rabbit primary skeletal myotubes were grown for
out 0.2 μM of Ca2+-ionophore A23187, as indicated. As markers of anaerobic-glycolytic
ctivity were determined. As markers of aerobic-oxidative energy metabolism (D) HK-2
present the mean±SD of 3 to 21 experiments. Data from untreated myotubes grown in
nt from myotubes in 5.55 mM glucose, with or without Ca2+-ionophore as indicated,
or 5.55 mM, or 25 mM glucose, without Ca2+-ionophore, pb0.05.
Fig. 2. High glucose conditions and ChREBP induce a metabolic “slow-to-fast”, whereas Ca2+-ionophore induces a metabolic “fast-to-slow” transformation in C2C12 myotubes.
C2C12 myoblasts were transiently transfected with (A) a−2.2 kb GAPDH or (B) a−2.3 kb ACAA-2, promoter luciferase reporter gene construct alone, or were co-transfected with
mChREBP expression plasmid pCMVS4-ChREBP or the empty expression vector, as indicated. Cells were grown for 24 hours in GM and then for 2 additional days in DM containing
5.55 mM or 25 mM glucose, with or without 0.1 μM of Ca2+-ionophore A23187, as indicated. The promoter activity is expressed as relative light units per ß-galactosidase (RLU/ß-
Gal). The data represent the mean±SD. *=signiﬁcantly different from myotubes grown in 5.55 mM glucose under the same treatment, p b0.05. + = signiﬁcantly different from
control myotubes grown in 5.55 mM glucose, p b0.05. ˆ = signiﬁcantly different from control myotubes grown in 25 mM glucose, p b0.05. (C) Western blot analysis of ChREBP
expression in non-transfected C2C12 myotubes, or C2C12 cells transiently transfected with mChREBP or the empty expression vector, or cells transfected with a pool of
doublestranded 20–25 nt siRNA that speciﬁcally target mouse ChREBP (siRNA ChREBP) or with non-speciﬁc doublestranded control siRNA (siRNA control), using an anti-ChREBP
antibody. The blot was reprobed with anti-histone H3 antibody as loading control.
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Ca2+-ionophore-treatment.
To test whether HG conditions can also induce a slow-to-fast
transformation of genes of the contractile apparatus, we transiently
transfected C2C12 cells with a−2.4 kb MHCI/β and a –2.8 kb MHCIId/
x promoter luciferase reporter gene construct. HG increased the
activity of the MHCIId/x promoter, whereas the activity of the MHCI/β
promoter was not altered (Fig. 3A). EndogenousMHC transcript levels
were assessed by semiquantitative RT-PCR. In accordance with the
promoter data, MHCI/β mRNA levels were comparable under LG and
HG conditions, while an increase in MHCIId/x mRNA expression was
found under HG compared with LG (Fig. 3B). To conclude, HG
conditions do not induce a full ﬁber type transformation on the level
of MHC promoter activity, but do increase MHCIId/x promoter
activity. Thus, HG induces several important but not all elements of
a complete slow-to-fast transformation. In contrast, 0.1 μM Ca2+-
ionophore leads to increased MHCI/ß and to decreased MHCIId/x
promoter activity together with changes in metabolic markers studied
that are all opposite towhat is seen under HG conditions (Figs. 1 and 2).
Thus, Ca2+-ionophore-treatment can induce a complete fast-to-
slow transformation.
3.2. ChREBP is involved in glucose-dependent metabolic
“slow-to-fast” transformation
The transcription factor ChREBP was shown to be of vital
importance for the induction of the glycolytic and lipogenic genes
L-PK, ACC and FAS by glucose in hepatocytes [30]. To test the impact of
ChREBP on GAPDH and ACAA-2 promoter activities inmuscle cells, we
ﬁrst overexpressed ChREBP in C2C12myotubes. Western blot analysis
demonstrated an increase of ChREBP protein expression in cells
transfected with pChREBP (Fig. 2C). Overexpression of ChREBP,similar to elevated glucose supply, increased the GAPDH promoter
activity and reduced the promoter activity of ACAA-2 (Fig. 2A and B).
The activating effect of HG on GAPDH promoter activity and its
inhibiting effect on ACAA-2 promoter activity were present under
control as well as under ChREBP overexpression conditions. It is
apparent, however, from Fig. 2A that the effect of HG on the GAPDH
promoter is considerably greater in the presence of ChREBP over-
expression than under control conditions, the increase in RLU/β-
Gal×104 observed by raising glucose from 5.55 to 25 mM amounting
to~100 under control conditions, and to~300 under ChREBP over-
expression. These results demonstrate 1) that overexpression of
ChREBP can induce changes in metabolic marker enzymes indicative
of a metabolic “slow-to-fast” ﬁber type transformation, and they
show 2) that ChREBP markedly increases the effect of glucose on
GAPDH and ACCA-2 promoter activities. Like the effect of glucose,
the effect of ChREBP occurs in a direction opposite to that of Ca2+-
ionophore (Fig. 2). Overexpression of ChREBP in C2C12 myotubes in
the presence of 0.1 μM Ca2+-ionophore (Fig. 2A and B, right hand
columns) results in intermediate promoter activities between those
found with Ca2+ ionophore and those with overexpressed ChREBP
alone.
To further examine the role of ChREBP for GAPDH and ACAA-2
promoter activity, we transiently transfected C2C12 cells with double-
stranded mouse ChREBP siRNA in an RNA interference experiment.
Western blot analysis revealed a signiﬁcant decrease in ChREBP
protein expression in myotubes transfected with speciﬁc ChREBP
siRNA but not in cells transfected with non-speciﬁc control siRNA or
non-transfected cells (Fig. 2C). Silencing of ChREBP resulted in
decreased GAPDH promoter activity and increased activity of the
ACAA-2 promoter under LG and HG conditions, but ChREBP silencing
did not entirely abolish the activating effect of HG on GAPDH but
increased the reducing effect of HG on ACAA-2 promoter (Fig. 4A
Fig. 3. High glucose conditions induce a partial slow-to-fast transformation on the level of MHC isoforms. (A) C2C12 myoblasts were transiently transfected with a−2.4 kb MHCI/ß
or a−2.8 kb MHCIId/x promoter luciferase reporter gene construct, as indicated. Cells were grown for 24 hours in GM and then for 2 additional days in DM containing 5.55 mM or
25 mM glucose, with or without 0.1 μM of Ca2+-ionophore A23187, as indicated. The promoter activity is expressed as relative light units per ß-galactosidase (RLU/ß-Gal). The data
represent the mean±SD. *=signiﬁcantly different frommyotubes grown in 5.55 mM glucose, p b0.05. += signiﬁcantly different frommyotubes grown in 25 mM glucose without
Ca2+-ionophore, p b0.05. (B) Semiquantitative RT-PCR analysis of MHCI/ß and IId/x mRNA expression in C2C12 myotubes. Total RNA was isolated from C2C12 cells grown for
24 hours in GM and then for additional 3 d in DM containing 2.75 mM, or 5.55 mM or 25 mM glucose. PCR products were separated on a 2% agarose gel and visualized with ethidium
bromide staining. 18s rRNA levels were used for normalisation.
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25 mM vs. 5.55 mM glucose on GAPDH promoter RLU/β-Gal under
siChREBP treatment (ΔRLU/β-Gal≈35) is more strongly reduced than
under control conditions (ΔRLU/β-Gal≈80), and the diminishing
effect of elevated glucose on ACAA-2 promoter RLU/β-Gal under
siChREBP treatment (ΔRLU/β-Gal≈18) is markedly greater com-
pared to the control situation (ΔRLU/β-Gal≈8). These ﬁndings show,
in analogy to ChREBP overexpression, that 1) although ChREBP is
important for GAPDH and ACAA-2 promoter activity under HG as well
as LG conditions, 2) ChREBP ampliﬁes the glucose effect on GAPDH as
well as ACAA-2 promoter activity and thus appears to be involved in
its mediation.
The effects of ChREBP overexpression and silencing on GAPDH
promoter activity led us to search for a ChREBP binding site (ChoRE)
in the GAPDH promoter. A putative ChoRE was identiﬁed at −1545/
−1529 bp. To test the functional relevance of this site wemutated the































Fig. 4. LXR induces an incomplete metabolic “slow-to-fast” transformation in C2C12 myotu
−2.3 kb ACAA-2 promoter luciferase reporter gene construct, as indicated. Cells were grown
glucose, with or without 10 μMof LXR agonist T0901317 (T), as indicated. In some experimen
25 nt siRNA that speciﬁcally target mouse ChREBP (siRNA ChREBP), or mouse LXRα (si LXRα)
for 2 additional days in DM. The promoter activity is expressed as relative light units per ß-g
from myotubes grown in 5.55 mM glucose under the same treatment, p b0.05. + =
ˆ=signiﬁcantly different from control myotubes grown in 25 mM glucose, p b0.05.ATA. Luciferase reporter gene assays showed that the activity of the
mutated promoter was reduced but not abolished under LG as well as
HG conditions (Fig. 5A). Also, the activating effect of HG versus LGwas
reduced albeit not quite abolished by the mutation. These ﬁndings
demonstrate the functional signiﬁcance of the ChoRE at −1545/
−1529 for GAPDH promoter activity. In accordance with over-
expression and RNA interference experiments, these data show that
ChREBP is involved in mediating the glucose effects on the GAPDH
promoter. However, since glucose effects are preserved under ChREBP
silencing as well as with the mutated ChoRE of the promoter, ChREBP
apparently cannot fully account for the action of glucose.
To conﬁrm ChREBP binding to the ChoRE at −1545/−1529 bp in
the GAPDH promoter in the context of native chromatin, a ChIP assay
was performed (Fig. 5B). This experiment revealed already under LG
condition some binding of ChREBP to the ChoRE in the GAPDH
promoter, which increased under HG conditions. These ﬁndings led us





























bes. C2C12 myoblasts were transiently transfected with (A) a −2.2 kb GAPDH or (B) a
for 24 hours in GM and then for 2 additional days in DM containing 5.55 mM or 25 mM
ts, cells grown for 24 hours in GMwere cotransfected with a pool of doublestranded 20–
, or a non-speciﬁc doublestranded control siRNA (control), as indicated, and then grown
alactosidase (RLU/ß-Gal). The data represent the mean±SD. *=signiﬁcantly different
signiﬁcantly different from control myotubes grown in 5.55 mM glucose, p b0.05.
Fig. 5. A carbohydrate response element (ChoRE) is important for GAPDH promoter activity under low and high glucose conditions. (A) C2C12myoblasts were transiently transfected
with a−2.2 kb with type (wt) GAPDH promoter luciferase reporter gene construct or a−2.2 kb GAPDH promoter construct mutated in the putative ChoRE (mut). Cells were grown
for 24 hours in GM and then for 2 additional days in DM containing 5.55 mM or 25 mM glucose. The promoter activity is expressed as relative light units per ß-galactosidase (RLU/ß-
Gal). The data represent the mean±SD. *=signiﬁcantly different frommyotubes grown in 5.55 mM glucose, p b0.05. += signiﬁcantly different from wt under 5.55 mM glucose, p
b0.05. ˆ = signiﬁcantly different from wt under 25 mM glucose, p b0.05. (B) ChIP assay to show binding of ChREBP to the native GAPDH promoter in C2C12 muscle cells grown in
medium containing 5.55 mM or 25 mM glucose. Soluble chromatin extracts were incubated with anti-ChREBP antibody, or non-immune IgG, or without antibody (input), as
indicated. Immunoprecipitated DNA was analysed with PCR using primers spanning the -1650/-1449 bp GAPDH promoter region which contains the putative ChoRE. PCR products
were separated on a 2% agarose gel and stained with ethidium bromide. (C) Western blot analysis of the intracellular localisation of ChREBP in C2C12 myotubes demonstrates
increased nuclear ChREBP under high glucose. C2C12 cells grown for 2 days in DM containing 5.55 mM or 25 mM glucose, were incubated with cell fractionation buffer for 5 min.
Cells were incubated in 0.1% NP40, then centrifuged, and pellet fraction (N) and supernatant fraction (C) were treated in Laemmli sample buffer. Aliquots were analysed using anti-
ChREBP or p53 (as nuclear control) antibodies, followed by incubation with horseradish peroxidase-conjugated secondary antibodies.
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nuclear proteins showed that, consistent with the ChIP results, a small
amount of ChREBP in the nuclei of myotubes under LG conditions
(Fig. 5C). However, under HG a decrease of cytosolic and an increase
of nuclear ChREBP protein were found. Taken together, HG supply
leads to increased nuclear accumulation of ChREBP, which correlates
with increased binding to the GAPDH promoter.
3.3. PP2A mediates glucose effects on GAPDH and MHCIId/x
promoter activity
In liver, the effects of increased [glc]e on the expression of
lipogenic genes are mediated via the glucose metabolite X-5-P, which
activates PP2A and by this leads to dephosphorylation and activation
of the transcription factor ChREBP [18]. To investigate a possible role
of PP2A in mediating the glucose effect on GAPDH and MHCIId/x
promoter activities, we used the inhibitor okadaic acid (OA). OA in a
concentration of 10 nM completely inhibits PP2A but has only a minor
effect on protein phosphatase 1 (PP1) [57]. Addition of 10 nM OA to
the medium reduced the activity of the GAPDH promoter signiﬁcantly
already under LG, but markedly more under HG (Fig. 6A). It is
apparent that under OA the activating effect of HG vs. LG is greatly
reduced but not completely abolished. Analogously, the activity of the
MHCIId/x promoter was decreased under LG, but to a much greater
extent under HG conditions by 10 nM OA. Again, the effect of HG vs.
LG was greatly reduced but not completely abolished in the presence
of OA (Fig. 6B). These data demonstrate that PP2A mediates at least in
part the activating effects of glucose on the GAPDH and MHCIId/x
promoters.
We have previously shown that p38MAPK is crucial for the activity
of the MHCIId/x promoter and MHCIID/X protein expression in C2C12
and primarymyotubes [58]. Thus, we checked phosphorylation of p38
MAPK to investigate activation under LG and HG conditions. Western
blot analysis demonstrates no change in total p38 MAPK expression
under HG compared with LG (Fig. 6C). Phosphorylation of p38 MAPK
(p-p38 MAPK) however, is increased under HG compared with LG,
indicating that p38 MAPK activation is augmented. Inhibition of PP2A
by 10 nM OA under HG decreased p-p38 MAPK to levels observed
under LG, indicating decreased activity of p38 MAPK. Taken together,
PP2A inhibition reduces both p-p38 and MHCIId/x promoter activityunder HG, and the change in p-p38 MAPK is presumably responsible
for the change in MHCIId/x promoter activity.
3.4. LXR induces an incomplete metabolic 'slow-to-fast' transformation
Since the nuclear receptors LXRα and LXRβ have been shown to be
activated by glucose and G-6-P in vitro [19] and are postulated to
target the ChREBP promoter [36], we wanted to establish whether
LXRs contribute to the metabolic transformation induced by glucose.
For this purpose, we employed LXR agonists, which can activate both
LXRα and LXRβ [59], in primary myotubes for 4 days. Activation of
LXRs with two different agonists, T0901317 (5 μM) and GW3965
(5 μM), increased the mRNA level of the glycolytic marker GAPDH
under LG as well as HG conditions (Fig. 7B). The expression of markers
of oxidative metabolism, PGC-1α and CS, did not change under
treatment with T0901317 or GW3965 (Fig. 7D and E), just like the
glycogen content of the myotubes (Fig. 7A). This indicates an increase
in anaerobic-glycolytic capacity, with oxidative capacity remaining
unaffected by LXR activation. Not entirely consistent with this
conclusion is the observation of an increase in HK-2 mRNA after
treatment with LXR agonists (Fig. 7C). This may be related to the
somewhat ambiguous role of HK-2 as a key enzyme in anaerobic-
glycolytic metabolism on one hand, and of being increased in slow-
twitch oxidative muscle ﬁbers on the other hand. In contrast to
treatment for 7 days with HG (Fig. 1), the effect of HG conditions after
4 days on GAPDH and HK-2 mRNA levels was seen but was not yet
signiﬁcant (Fig. 7B and C), indicating a time-dependency of these
changes. In C2C12 myotubes, treatment with 10 μM T0901317
resulted in increased GAPDH promoter activity and reduced activity
of the ACAA-2 promoter under both LG and HG conditions while
preserving the effect of HG (Fig. 4A and B). The former is in agreement
with an increased glycolytic energy metabolism (Fig. 7B), and the
latter indicates a decrease in fatty acid oxidation, in contrast to the
results shown for the other oxidative markers PGC-1α and CS (Fig. 7D
and E).
LXRα has been shown to be up-regulated in differentiating C2C12
myotubes [43]. We therefore chose LXRα siRNA in an RNA
interference experiment in C2C12 myotubes. In contrast to the
agonist effects (Fig. 4), silencing of LXRα with speciﬁc siRNA
decreased the GAPDH promoter activity and increased the promoter
Fig. 6. PP2A mediates glucose effects on GAPDH and MHCIId/x. C2C12 myoblasts were transiently transfected with (A) a −2.2 kb GAPDH or (B) a −2.8 kb MHCIId/x promoter
luciferase reporter gene construct, as indicated. Cells were grown for 24 hours in GM and then for 2 additional days in DM containing 5.55 mM or 25 mM glucose, with or without 10
nM of okadaic acid, as indicated. The promoter activity is expressed as relative light units per ß-galactosidase (RLU/ß-Gal). The data represent the mean±SD. *=signiﬁcantly
different from myotubes grown in 5.55 mM glucose under the same treatment, p b0.05. + = signiﬁcantly different from control myotubes grown in 5.55 mM glucose, p b0.05,
ˆ=signiﬁcantly different from control myotubes grown in 25 mM glucose, p b0.05. (C) Western blot analysis of p38 MAPK activation. C2C12 cells were grown for 2 days in DM
containing 5.55 mM or 25 mM glucose, with or without 10 nM okadaic acid, as indicated. Blots were probed with anti-phospho-p38 (Thr-180, Tyr-182) antibody and reprobed with
anti-p38 or anti-α-tubulin antibodies, followed by incubation with horseradish peroxidase-conjugated secondary antibodies.
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was preserved under both treatments. Finally, we investigated a
possible interference between ChREBP and LXR signalling on GAPDH
promoter activity. Combination of 10 μM T0901317 and ChREBP
siRNA resulted in intermediate GAPDH promoter activities between
those found under treatment with T0901317 and siChREBP alone,
comparable with the level of untreated controls (Fig. 4A). These
results, however, do not offer clues about themechanistic relationship
between ChREBP and LXR signalling. To summarize all data on LXR
effects, we ﬁnd an unequivocal increasing effect of LXR activation
upon the anaerobic–glycolyticmarker GAPDH as studied in primary or
C2C12 muscle cells, while oxidative markers are either unaffected
(PGC-1α, CS) or decreased by LXR activation (ACAA-2). Thus, LXR
appears to predominantly affect gylcolytic enzymes. These ﬁndings
indicate that LXR has a less comprehensive effect on the metabolic
markers than glucose and ChREBP, and is not able to induce a
complete metabolic “slow-to-fast” transformation.
To assess if the intracellular concentrations of glucose ([glc]i) or G-
6-P ([G-6-P]i) are sufﬁcient to activate LXRα or LXRβ in C2C12
myotubes, we measured these metabolites in C2C12 myotubes grown
with or without addition of 25 mM glucose for an additional 2 hours
after having grown for 24 hours in 5.55 mM glucose. Under LG
conditions, [glc]i was 0.010 mM, and increased to 6.0 mM under HG
conditions (Table 1). [G-6-P]i was 0.015 mM under LG compared with
0.061 mM under HG conditions. The [G-6-P]i necessary for half-
maximal activation of LXRα or LXRβ in vitro has been reported to be
5.0 mM and 1.4 mM, and the [glc]i necessary for half-maximalactivation of LXRα or LXRβ in vitro has been reported to be 3.0 mM
and 0.3 mM, respectively [19]. These results indicate that [G-6-P]i is
too low to activate either LXRα or LXRβ under both LG and HG
conditions in C2C12 myotubes. On the other hand, [glc]i under HG is
well above the EC50 for activation of LXRβ and also above that for
LXRα. These data indicate that G-6-P is not an activator of LXRs under
LG or HG conditions in C2C12 myotubes, whereas glucose is able to
activate LXRs at least under HG conditions.
4. Discussion
4.1. Effects of varying glucose exposure on muscle ﬁber type markers
The effects of increasing extracellular glucose from 5.55 mM to
25 mM on the expression and activity of marker enzymes of glycolytic
and oxidative energy metabolism have been investigated in a
previously established primary rabbit skeletal muscle culture
[11,12] and in the mouse C2C12 muscle cell line. We report here
that HG conditions induce a metabolic “slow-to-fast” transformation,
indicating that elevated [glc]e–along with elevated [glc]i–has a
profound inﬂuence on energy metabolism in skeletal muscle cells,
extending previous results [14]. In addition, glucose causes a marked
increase in MHCIId/x promoter activity and mRNA, while it does not
changeMHCI/β promoter activity andmRNA. Thus, HG conditions can
contribute substantially to a slow-to-fast transformation in cultured







































































































































Fig. 7. LXR induces an incomplete metabolic “slow-to-fast” transformation in primary skeletal myotubes. Fourteen day old rabbit primary skeletal myotubes were grown for 4
additional days in medium containing 0 mM, or 5.55 mM, or 25 mM glucose, with or without LXR agonists T0901317 (5 μM) or GW3965 (5 μM), as indicated. As markers of
anaerobic-glycolytic energy metabolism (A) glycogen content and (B) GAPDH mRNA level were determined. As markers of aerobic-oxidative energy metabolism (C) HK-2 mRNA
level, (D) PGC-1αmRNA level and (E) CS enzyme activity were measured. The data represent the mean±SD of 3 to 9 experiments. Data from untreatedmyotubes grown inmedium
containing 5,55 mM glucose (controls) were set to 100%. *=signiﬁcantly different frommyotubes in 5.55 mM glucose under the same treatment, pb0.05. ⊥=signiﬁcantly different
from untreated myotubes grown in 5.55 mM glucose, pb0.05. ˆ=signiﬁcantly different from untreated myotubes grown in 25 mM glucose, pb0.05.
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ously [14] under low glucose supply in vitro be involved in the
physiological fast-to-slow muscle ﬁber transformation as can be
induced by endurance exercise? In skeletal muscle, it has been shown
that intracellular glucose and G-6-P concentrations can be drastically
lowered after high-intensity and longer-lasting periods of exercise
[60,61]. Even in a repetitive exercise model with 6 min of exercise,
performed once per hour over a total period 16 hours, after a marked
initial increase in muscular glucose a strong trend of decreasing
muscular glucose and G-6-P concentrations from the end of each cycle
to the next one has been observed [62]. In several other relatively
moderate exercise protocols similar initial increases in muscular
glucose with a subsequent decrease during continued exercise were
observed, although ﬁnal glucose and/or G-6-P concentrations often
did not or did only slightly fall below their resting values [63–65]. We
conclude that lowered intracellular glucose and G-6-P concentrations
can prevail at the end of prolonged high-intensity endurance exercise
and thus may constitute a signal for induction of a partial fast-to-slow
transformation of skeletal muscle.
The metabolic proﬁle we observe here under HG in cultured
muscle cells is reminiscent of metabolic alterations occurring in
patients with type 2 diabetes showing an increased ratio of glycolyticTable 1
Intracellular metabolite concentrations of C2C12 myotubes grown in 5.55 mM or 25
mM glucose for additional 2 hours after 24 hours in 5.55 mM glucose. Data represent
the mean±SD of 4–5 experiments. *=signiﬁcantly different from myotubes in 5.55





5.55 mM Glucose 0.015±0.002 0.010±0.005
25 mM Glucose 0.061±0.002 * 6.0±1.0 *to oxidative enzymes [7–9]. Whether changes in ﬁber type and
oxidative capacity are cause or consequence of the pathophysiology of
insulin resistance and type 2 diabetes is not yet clear.4.2. Mediation of glucose effects on ﬁber type markers by ChREBP
Even though the function and regulation of ChREBP has been
intensively studied in liver, only few reports are available about the
role of ChREBP in skeletal muscle. In vivo, a diet high in carbohydrates
activates ChREBP activity in liver, whereas a diet high in fat inhibits it
[21]. In human vastus lateralis muscle after fasting, a decrease of
ChREBP mRNA has been shown, although this was not signiﬁcant
[66]. Using overexpression, RNA interference and mutation studies,
we demonstrate here that ChREBP, like HG, can induce a metabolic
“slow-to-fast” transformation. The effects of LG and more so of HG on
metabolic markers were increased by overexpression of ChREBP,
leading to an augmented shift of marker enzymes of energy
metabolism. The reverse observations were made with ChREBP
mRNA interference. A functional ChoRE was identiﬁed in the GAPDH
promoter, which further supports a role for ChREBP in the regulation
of GAPDH expression. We conclude that ChREBP is important in
mediating the glucose effects on the GAPDH promoter, but our data
also suggest that ChREBP is not the only contributing factor.
Interestingly, a paralog of ChREBP, MondoA, has been implicated in
the regulation of glycolytic markers in C2C12 myoblasts [67].
Nevertheless, MondoA shows only a minor nuclear translocation in
response to increased glucose in L6 myoblasts or myotubes [68,69].
Thus, whether MondoA can play a role in glucose-dependent
metabolic ﬁber type transformations of myotubes remains to be
elucidated. The molecular basis of the inhibitory action of ChREBP on
the ACAA-2 promoter is not yet clear and needs further investigation.
Recently, a repressive effect of ChREBP on aryl hydrocarbon receptor
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expression has been demonstrated, with ChREBP binding to a
proximal promoter region which confers negative glucose respon-
siveness [70].
At least in hepatocytes, ChREBP function is regulated by glucose-
dependent dephosphorylation of different residues, which induces
nuclear localisation and promotes DNA binding [24]. We now
demonstrate in cultured muscle cells that HG conditions lead to
increased nuclear accumulation and increased binding of ChREBP to
the GAPDH promoter in C2C12 myotubes. This appears at variance
with a report that ChREBP binding to promoter regions of L-PK and
FAS in primary rat hepatocytes is not signiﬁcantly affected by glucose
supply [71]. Furthermore, small amounts of ChREBPwere found in the
nuclei by immunoblotting even in medium containing 0 mM glucose.
For primary hepatocytes, on the other hand, it was reported
previously from immunoﬂuorescence studies that under low glucose
(5.5 mM) ChREBP is nearly completely localised in the cytoplasm [24].
Yet another situation was observed in pancreatic MIN6 β-cells, where
ChREBP binding to the promoters of L-PK and FASwas absent in 3 mM
glucosemedium although around 25% of cells exhibited both cytosolic
and nuclear ChREBP; at 30 mM extracellular glucose, however,
signiﬁcant ChREBP binding to these promoters was detected via
ChIP assays [72]. Strikingly, in another β-cell line, 832/13, even under
high glucose a predominantly cytoplasmic localisation of ChREBP was
observed together with nucleo-cytoplasmic shuttling under high as
well as low glucose [27–29,73]. The authors reported a glucose-
dependent relief of intramolecular transcriptional repression in
conjunction with an interaction with the molecular chaperone 14-
3-3. These ﬁndings suggest that the regulation of ChREBP function,
including intracellular localisation of ChREBP and glucose-sensitivity
of ChREBP-binding to different promoters, depend critically on cell
type and may vary from what is observed here in myotubes.
4.3. Role of PP2A in mediating glucose effects
In liver, the effects of increased [glc]e on the expression of
lipogenic genes are mediated via the glucose metabolite X-5-P, which
activates PP2A, and PP2A dephosphorylates and activates the
transcription factor ChREBP [18]. It is likely that in the present
experiments X-5-P increases with increasing glucose and G-6-P
concentration (Table 1) and is responsible for the glucose-dependent
activation of ChREBP. Although we failed to measure X-5-P levels in
myotubes, our ﬁnding of a role of PP2A in the glucose effects on
GAPDH and MHCIId/x promoters shows that glucose presumably
leads to an increase in PP2A activity. Increase of X-5-P is a likely
candidate for the activation of PP2Awhen [glc]e is raised [25,74]. As an
additional mechanism, a direct effect of glucose on the glucose-
sensing module of ChREBP [27,28] cannot be excluded.
PP2A is shown here to mediate the effect of HG on MHCIId/x
promoter activities in C2C12 myotubes, and in addition to affect the
basal level of activity under LG conditions (Fig. 6B). We propose p38
to constitute the link between PP2A and theMHCIId/x promoter. PP2A
has been shown to positively inﬂuence the level of activated p38
MAPK [75], and the present data show indeed that p-p38 is higher
under HG than LG conditions, and this increase is dependent on PP2A.
As we have previously demonstrated the importance of p38α/βMAPK
for MHCIID/X protein expression and MHCIId/x promoter activity in
primary and C2C12 myotubes [58], we suggest therefore that the
activating effect of HG on MHCIId/x is caused by increased activation
of p38 MAPK.
4.4. Role of LXR in mediating glucose effects
In cultured human myotubes from lean and diabetic (type 2)
individuals, LXR has repeatedly been shown to promote intracellular
lipid synthesis and accumulation, possibly also by enhanced uptake ofglucose [44–46]. However, the evidence for the latter is equivocal.
Taking into account data obtained with the endogenous LXR ligand,
22-R-hydroxycholesterol [46], it is also not clear whether LXR favours
glucose oxidation in myotubes. The data presented in our study show,
on the basis of the effects of LXR agonists and LXRα silencing, that LXR
increases the effects of LG and HG on the marker of glycolytic energy
metabolism (Figs. 4 and 7). We also show that, in contrast to the clear
LXR-mediated increase in the glycolytic marker, the effect of LXR on
oxidative markers in the presence of glucose is non-uniform: LXR
activators lead to a decrease of ACAA-2 promoter activity in C2C12
cells, and LXRα silencing leads to the corresponding increase in ACAA-
2 promoter activity (Fig. 4), thus both observations indicate decreased
fatty acid β oxidation. On the other hand, LXR activation shows no
effect on the oxidativemarkers PGC-1α and CS (Fig. 7), where the lack
of an effect on PGC-1α is in agreement with Cozzone et al. [45] and
Lafﬁtte et al. [76]. Thus, the effects of LXRs on oxidative markers are
equivocal, but LXRs can be expected to contribute to the increase in
the glycolytic marker associated with the glucose-mediated “slow-to-
fast” metabolic transformation, which is likely to be triggered mainly
by other mechanisms. In conclusion, LXR seems to be an important
mediator of the glucose response of myotubes, but provides only a
limited contribution to the overall “slow-to-fast” metabolic transfor-
mation induced by glucose.
4.5. Ionophore effects on ﬁber type markers
Addition of Ca2+-ionophore A23187 to the culture medium leads
to an increase in [Ca2+]i in primary rabbit myotubes [11,17]. Increased
[Ca2+]i during muscle activation is thought to underlie fast-to-slow
transformation in muscle gene expression [11,17,77]. Calcineurin has
been shown to be involved in mediating changes in the expression of
MHC isoforms as well as enzymes of energy metabolism [3,4,78]. The
present paper demonstrates that Ca2+-ionophore can induce a
metabolic “fast-to-slow” transformation in medium without glucose
as well as under LG and HG conditions. Thus, the effects of Ca2+-
ionophore, which are consistently inverse to the effects of HG, are
independent of [glc]e. Nevertheless, the ability of glucose to induce
changes in metabolic enzymes towards higher anaerobic-glycolytic
capacity is generally preserved under Ca2+-ionophore-treatment.
This does not hold for CS enzyme activity, but glucose remains able to
reduce PGC-1αmRNA in the presence of ionophore (Fig. 1). Similarly,
the effects of ChREBP expression are preserved in Ca2+-ionophore-
treated myotubes under LG and HG conditions. Thus, the effects of
glucose and ChREBP onmusclemetabolism andMHC expression seem
to be independent of the effects of Ca2+.
5. Conclusions
To summarize, we show that both HG conditions and Ca2+-
ionophore are able to induce metabolic transformation in muscle cell
cultures, albeit in opposite directions. The fast-to-slow transformation
induced by Ca2+-ionophore is complete with respect to MHC isoforms
and markers of energy metabolism. In contrast, HG conditions lead to
increased anaerobic-glycolytic and decreased oxidative capacity in
addition to an activation of fast MHCIId/x expression, but do not
change slow MHCI/β expression. Ca2+-ionophore-treatment can
induce the metabolic transformation independent from [glc]e. In
turn, glucose effects are seen also under Ca2+-ionophore, indicating
that both signals act independently. The effects of HG on GAPDH and
MHCIId/x are mediated by PP2A. PP2A also contributes, presumably
indirectly, to the activation of p38 MAPK, which in turn regulates
transcription of MHCIId/x. The glucose-dependent transcription factor
ChREBP, which is downstream of PP2A, can increase the glucose effect
on GAPDH and ACAA-2 under LG and HG conditions independently
from [Ca2+]i. Our ﬁndings lead to the conclusion that ChREBP is amain
mediator of the effects of glucose on energy metabolism. In contrast,
388 N. Hanke et al. / Biochimica et Biophysica Acta 1813 (2011) 377–389LXRs essentially contribute to the glucose-dependent up-regulation of
anaerobic glycolysis. Some effects inverse to those reported here for
high glucose have been reported previously for the case of low glucose
[14]. We speculate that low intramuscular glucose, as it can be
observed at the end of long-lasting intense exercise [49–51], may be a
novel trigger of a partial fast-to-slow ﬁber type transformation, which
may act in addition to other established trigger mechanisms like
increased [Ca2+]i [11,17,77].
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